Dashboard
1
Poor Management Efficiency with a low ROCE of 0.38%
- The company has been able to generate a Return on Capital Employed (avg) of 0.38% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 17.13% and Operating profit at -294.98% over the last 5 years
3
The company has declared positive results in Mar'2025 after 5 consecutive negative quarters
4
Risky -
5
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,260 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
0.08
-5.52%
3.33
Revenue and Profits:
Net Sales:
190 Million
(Quarterly Results - Sep 2025)
Net Profit:
-10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
76.62%
0%
76.62%
6 Months
78.31%
0%
78.31%
1 Year
25.75%
0%
25.75%
2 Years
20.36%
0%
20.36%
3 Years
81.57%
0%
81.57%
4 Years
-17.48%
0%
-17.48%
5 Years
0%
0%
0.0%
Jiangsu Aidea Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.13%
EBIT Growth (5y)
-294.98%
EBIT to Interest (avg)
-26.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.30
Tax Ratio
15.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.38%
ROE (avg)
0.68%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.17
EV to EBIT
-35.92
EV to EBITDA
-115.88
EV to Capital Employed
3.00
EV to Sales
5.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.35%
ROE (Latest)
-8.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
189.90
164.60
15.37%
Operating Profit (PBDIT) excl Other Income
-0.70
10.80
-106.48%
Interest
3.80
3.80
Exceptional Items
-5.90
5.00
-218.00%
Consolidate Net Profit
-10.40
0.90
-1,255.56%
Operating Profit Margin (Excl OI)
-3.90%
-26.90%
2.30%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 15.37% vs -16.83% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -1,255.56% vs -96.48% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
412.20
409.00
0.78%
Operating Profit (PBDIT) excl Other Income
-94.90
-58.30
-62.78%
Interest
15.50
11.80
31.36%
Exceptional Items
-18.20
1.50
-1,313.33%
Consolidate Net Profit
-138.80
-76.10
-82.39%
Operating Profit Margin (Excl OI)
-367.70%
-259.20%
-10.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.78% vs 67.76% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -82.39% vs 38.68% in Dec 2023
About Jiangsu Aidea Pharmaceutical Co., Ltd. 
Jiangsu Aidea Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






